1. Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma
   Keiichi Ito et al, 2019, Japanese Journal of Clinical Oncology CrossRef
2. Biomarkers Towards New Era of Therapeutics for Metastatic Renal Cell Carcinoma
   Ryuichi Mizuno et al, 2020, Kidney Cancer CrossRef
3. Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival
   Jun Teishima et al, 2018, Urologic Oncology: Seminars and Original Investigations CrossRef
4. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma
   Kosuke Ueda et al, 2018, Urologic Oncology: Seminars and Original Investigations CrossRef
5. Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma
   Nobuki Furubayashi et al, 2017, Molecular and Clinical Oncology CrossRef
6. Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
   Yosuke Yasuda et al, 2017, International Journal of Clinical Oncology CrossRef
7. Editorial Comment from Dr Teishima and Dr Matsubara to Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first‐line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma
   Jun Teishima et al, 2018, International Journal of Urology CrossRef
8. Prognostic Value of Baseline Serum C-Reactive Protein Level in Intermediate-Risk Group Patients With Metastatic Renal-Cell Carcinoma Treated by First-Line Vascular Endothelial Growth Factor–Targeted Therapy
   Kimiharu Takamatsu et al, 2018, Clinical Genitourinary Cancer CrossRef
9. The effect of kinetics of C-reactive protein in the prediction of overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor
   Jun Teishima et al, 2017, Urologic Oncology: Seminars and Original Investigations CrossRef
10. CRP and Cancer
    Waliza Ansar et al, 2016, Biology of C Reactive Protein in Health and Disease CrossRef
11. Prediction of early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor
    Jun Teishima et al, 2021, Current Urology CrossRef
12. Prognostic effect of serum C-reactive protein kinetics on advanced renal cell carcinoma treated with sunitinib
    Tetsuo Fujita et al, 2017, Molecular and Clinical Oncology CrossRef
13. C-Reactive Protein and Cancer—Diagnostic and Therapeutic Insights
    Peter C. Hart et al, 2020, Frontiers in Immunology CrossRef
14. Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study
    Yoshihiko Tomita et al, 2019, BMC Cancer CrossRef
15. Editorial Comment to C‐reactive protein can be used to predict the therapeutic effects of nivolumab in patients with metastatic renal cell carcinoma
    Teruo Inamoto et al, 2019, International Journal of Urology CrossRef
16. Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor
    Kazuma Yukihiro et al, 2022, Urologic Oncology: Seminars and Original Investigations CrossRef
17. The impact of change in serum C‐reactive protein level on the prediction of effects of molecular targeted therapy in patients with metastatic renal cell carcinoma
    Jun Teishima et al, 2016, BJU International CrossRef
18. C-reactive protein is a predictor of prognosis in renal cell carcinoma patients receiving tyrosine kinase inhibitors: A meta-analysis
    Zhun Wang et al, 2017, Clinica Chimica Acta CrossRef
19. Evaluating the Prognostic Variables for Overall Survival in Patients with Metastatic Renal Cell Carcinoma: A Meta-Analysis Of 29,366 Patients
    Bruce Li et al, 2024, JU Open Plus CrossRef
20. Metastasectomy for metastatic renal cell carcinoma in the era of modern systemic treatment: C‐reactive protein is an independent predictor of overall survival
    Steffen Rausch et al, 2016, International Journal of Urology CrossRef